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Background: Bladder cancer is a disease frequently seen in the elderly. Frail and elderly patients with
muscle-invasive bladder cancer (MIBC) are often unﬁt for surgery. While concurrent chemoradiotherapy
(CCRT) is a well-established alternative treatment modality, only a small proportion of elderly patients
receive CCRT. The purpose of this article is to review our experience with CCRT in elderly MIBC patients.
Methods: Between January 1, 2007 and December 31, 2013, we retrospectively reviewed patients aged
>75 who were treated with CCRT at Taipei Veterans General Hospital. Patients' characteristics, thera-
peutic strategy, clinical outcomes, and treatment-related toxicities were assessed.
Results: Nineteen patients (4 females and 15 males) were identiﬁed. The median age was 79.5 years
(range, 78.5e84.0 years) and the median follow-up was 33.7 months (interquartile range, 19.1e51.8
months). The major adverse event was grade 3 or grade 4 neutropenia, which developed in 10 of the 19
patients. No treatment-related mortality occurred. We found no association between prognosis and the
chemotherapy regimen. Chemotherapy with a conventional dose of gemcitabine (800e1000 mg/m2) was
well tolerated. The two-year and three-year estimated overall survival rates were 74% and 60%,
respectively.
Conclusion: CCRT after complete transurethral resection of the bladder tumor is feasible for elderly
patients with MIBC. The conventional dose of gemcitabine as a chemosensitizer is adequate in the elderly
population, but further investigation is needed.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bladder cancer is one of the most common cancers in the world.
It is estimated that around 74,000 new cases of bladder cancer and
16,000 bladder cancer-related deaths will occur in the United States
in 2015.1 It is prominent in men and in the elderly population. In
Taiwan, 2199 new cases of bladder cancer were reported in 2011.
The median age at diagnosis was 71 years.2nd Oncology, Department of
, Shipai Road, Sec. 2, Taipei
ncology Society.
Society. Production and hosting byRadical cystectomy with pelvic lymph node dissection is the
standard treatment for muscle-invasive bladder cancer (MIBC).3
Bladder-preserving approaches, including transurethral resection
of the bladder tumor (TURBT) followed by chemotherapy, radio-
therapy, or a combination of chemotherapy and radiotherapy are
alternatively strategies for patients unﬁt for radical cystectomy or
for elderly patients with increased risks of morbidity or mortality.
Radiotherapy is commonly used to treat MIBC, but radiotherapy
alone is inferior to radical cystectomy and combinations of con-
current radiosensitizing chemotherapy.4e6 Although concurrent
chemoradiotherapy (CCRT) provides a survival beneﬁt and allows
bladder preservation, CCRT in the elderly population is usually
underused.7,8 In Taiwan, only 6e7% of MIBC patients aged >70
received CCRT.2 In addition, the use of gemcitabine as radio-
sensitizing agent is rarely discussed.9e11Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient characteristics.
Variable N (%), median (range)
Gender
M 15 (78.9)
F 4 (21.1)
Age 79.5 (78.5e84.0)
Stage
T2N0 14 (73.6)
T2N1 2 (10.5)
T4N0 1 (5.2)
T4N3 1 (5.2)
Chemotherapy
GC 11 (57.9)
CMV 4 (21.1)
Others 4 (21.1)
Carboplatin base 8 (42.1)
AUC 4e6
Cisplatin base 10 (52.6)
Dose 35 (30e40) mg/m2
Radiation
Bladder ± Plevis 45 Gy (45e46)
Tumor 58.6 Gy (54e62.8)
Estimated GFR 42.3 (26.0e59.8) ml/min
Obstructive uropathy 6 (30.0)
Comorbidity
DM 9 (47.4)
HTN 12 (63.2)
CKD 9 (47.4)
CHF 2 (10.5)
COPD 3 (15.8)
CVA 4 (21.1)
CAD 8 (42.1)
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patients treated with CCRT.
2. Patients and methods
2.1. Patients
We reviewed the medical records of consecutive adult patients
with bladder cancer who were referrals from primary or secondary
health professionals or newly diagnosed at Taipei Veterans General
Hospital between January 2007 and December 2013. All cases were
pathologically conﬁrmed. The inclusion criteria included age >75
years, pathological diagnosis of urothelial carcinoma, newly diag-
nosed muscle-invasive bladder cancer, and patients receiving CCRT
after complete TURBT. Patients with prior non-MIBC or MIBC with
distant metastasis were excluded. Patients' clinical information,
including therapeutic strategies, toxicities and comorbidities, was
collected, and patients were followed until either death, loss of
follow-up or January 31, 2015.
2.2. Concurrent chemoradiotherapy
Either chemotherapy or radiotherapy was started within three
months of complete TURBT. Radiotherapy doses of 40e45 Gy were
used to treat the whole bladder and in some instances the pelvic
lymph nodes. Some patients also received a sequential boost to the
tumor bed for a total dose of 55e65 Gy. Chemotherapy was
administered concurrently with radiotherapy or in the peri-
radiotherapy period. Patients treated with sequential radiotherapy
after neoadjuvant chemotherapy were excluded from this study.
2.3. Outcomes and statistical analysis
Descriptive statistics were used to describe the patients' char-
acteristics, disease stages and treatment features, as well as
treatment-associated toxicities. Overall survival (OS) and
progression-free survival (PFS) were illustrated by means of the
KaplaneMeier estimate. Progression was deﬁned as development
of distantmetastasis or local recurrence of a bladder tumor. PFSwas
calculated from the date of TURBT to the date of the ﬁrst cysto-
scopic ﬁnding or radiographic evidence of disease progression,
death, or the last follow-up visit. Survival was calculated from the
date of TURBT to the date of death or the last follow-up visit. All
analysis was performed using IBM SPSS Statistics (version 21) and
conducted in February 2015.
3. Results
3.1. Patient characteristics
Between January 1, 2007 and December 31, 2013, we identiﬁed
44 patients receiving CCRT from a total of 933 patients with newly
diagnosed bladder cancer. Of these 44 CCRT patients, 19 patients,
including four women and 15 men, were aged over 75 and were
diagnosed with MIBC. Their median age was 79.5 years (inter-
quartile range, 78.5e84.0 years).
All enrolled patients hadMIBC with or without nodal metastasis
and were treated with complete TURBT and adjuvant CCRT. All
patients' ECOG performance status was between 0 and 1. Clinical
staging revealed that 14 patients were T2N0, two were T2N1, one
was T4N0 and one was T4N3. Eleven patients received gemcitabine
(800e1000 mg/m2, given on days 1 and 8 and repeated every 21
days) combined with cisplatin (day 1, repeated every 21 days) or
carboplatin (day 1, repeated every 21 days), 4 patients used CMV
(cisplatin, methotrexate and vinblastin), three patients usedweeklycarboplatin, and one patient took oral tegafur plus uracil daily for
three years. Eight patients used carboplatin-based chemotherapy
because of impaired renal function. Patients' characteristics are
summarized in Table 1.
3.2. Toxicity
Ten of the 19 patients developed grade 3 or grade 4 neutropenia,
but only one patient had febrile neutropenia and needed hospi-
talization. Chemotherapy with gemcitabine showed no associated
risk of neutropenia. Four patients had grade 1 or grade 2 renal
toxicity, and two patients experienced grade 3 hepatic toxicity.
Both renal and hepatic injuries resolved completely after adjusting
or discontinuing chemotherapy. No treatment-related mortality
was observed in this study (Table 2).
Radiation-associated cystitis developed in one patient. Two
patients experienced radiation colitis and one was hospitalized.
Radiation-associated dermatitis was noted in one patient. One
patient withdrew from chemotherapy after two cycles but
completed radiotherapy. Furthermore, reactivation of hepatitis B
happened in one patient and subsided after treatment with ente-
cavir and termination of chemotherapy.
3.3. Overall survival and PFS
Overall, the median follow-up was 33.7 months (interquartile
range, 19.1e51.8 months) and the PFS was 27.9 months (inter-
quartile range, 14.5e44.2 months) (Fig. 1). At the time of analysis, 5
patients had progressed, including 2 patients with local recurrence
and 3 patients with distant metastasis. Six patients died d ﬁve
from disease progression and one from ischemic bowel disease. The
two-year and three-year overall survival rates were 74% and 60%,
respectively. We found no signiﬁcant association between prog-
nosis and chemotherapy regimens.
Table 2
Patient outcomes.
Variable N (%), median (range)
Follow-up 33.7 (19.1e51.8) months
Progression-free-survival 27.9 (14.5e44.2) months
PD
Local recurrence 2 (10.5)
Distant metastasis 3 (15.8)
Neutropenia
Grade I/II 9 (47.4)
Grade III 6 (31.6)
Grade IV 4 (21.1)
Renal injury
Grade I/II 3 (21.1)
Grade III/IV 0
Liver injury
Grade I/II 1 (5.3)
Grade III/IV 2 (10.5)
Others
Radiation associated cystitis 1
Radiation colitis 2
Dermatitis 1
Febrile neutropenia 1
Fig. 1. Progression-free survival.
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Treating elderly patients with MIBC can be challenging, but
aggressive treatment of bladder cancer may improve survival in the
elderly population.12 Radical cystectomy is still the standard
treatment for MIBC. Alternative options include partial cystectomy
and bladder preservation approaches.3 However, elderly patients
and their physicians may be concerned about the mortality and
morbidity associated with surgery, and other aspects of treatment,
including organ preservation, quality of life, and the physical con-
dition needed for tolerating treatment-related toxicity. Curative
therapy, including cystectomy and aggressive bladder-preserving
therapies for non-cystectomy patients, is underused in the elderly
population.8
Radical cystectomy with pelvic lymph node dissection is often
performed on healthy young patients with MIBC. In a series of1054 patients, the overall recurrence-free survival at ﬁve and 10
years for the entire cohort was 68% and 66%, respectively. Gener-
ally, 2.5% of the patients faced perioperative deaths and 28% of the
patients had early complications.13 Recently, Leveridge and col-
leagues conducted a retrospective study involving 3320 patients
with age stratiﬁed as <70, 70e74, 75e79 and 80 years, with the
ﬁve-year overall survival at 40%, 34%, 28% and 23%, respectively. It
is not surprising that early mortality increased with age due to
decline of functional reserves and loss of homeostasis.14 Overall,
the early perioperative mortality in the elderly population was up
to 9.5% at 30 days and 11% at 90 days.15 In addition, patients
treated with radical cystectomy may have to sacriﬁce their quality
of life.16
Radiotherapy with concurrent chemotherapy after complete
TURBT is equivalent to radical cystectomy and more effective than
radiotherapy alone after TURBT.6,7,17 In general, pooled analyses
showed the ﬁve-year overall survival rate to be around 60%.17e20
Turgeon et al further reviewed the outcomes of CCRT after TURBT
in patients aged S65 with MIBC. The two-year and three-year
overall survival rates were between 33% and 93% and between
34% and 88%, respectively.7 In our study, the respective two-year
and three-year overall survival rates were 74% and 60%.
In contrast to the relatively high perioperative mortality or early
complications of radical cystectomy, CCRT toxicity after TURBT is
more tolerable for non-surgical candidates. Grade 3e4 acute
toxicity was reported in up to 43% of elderly patients.7 Compared
with earlier data, the most prominent acute toxicity we observed
was neutropenia (grade 3e4, 44%). Otherwise, the majority of our
patients withstood the entire treatment process. One patient
withdrew from chemotherapy and another two patients were
hospitalized due to acute toxicity. While our patients were highly
selected, our observations reﬂect the reality that patients and
physicians chose CCRT after TURBT because of the low treatment-
related mortality.
Cisplatin-based chemotherapy is commonly used in adjuvant
CCRT,3 but data on carboplatin-based chemotherapy with radio-
therapy is lacking. Khoury et al reported that patients treated with
carboplatin-based chemoradiotherapy show worse outcomes.
However, the impact on patient comorbidities was not reported,21
and patients treated with carboplatin usually have impaired renal
function. In this study, eight patients were treated with a
carboplatin-based regimen. We found no correlation between
carboplatin-based regimens and outcomes. The combination of
gemcitabine plus cisplatin is usually used to treat metastatic
bladder cancer.22 Some prospective studies have been conducted
using low doses of gemcitabine as a chemosensitizer with radio-
therapy.9e11 Our study showed that elderly patients can tolerate
and ﬁnish conventional doses of gemcitabine (800e1000 mg/m2,
given on days 1 and 8 and repeated every 21 days).
Our study has several limitations. First, it is limited by its
retrospective nature. Second, compared to patients treated with
radiotherapy alone or TURBT alone, patients receiving CCRT after
TURBT included in this analysis were highly selected. They have
stronger physical reserves and less comorbidities. Third, late pelvis
toxicity and quality of life could not be assessed comprehensively.23
Finally, the number of cases is inadequate for contributing a sig-
niﬁcant ﬁnding in multivariate analysis and survival analysis.
In conclusion, our study shows that CCRT after complete TURBT
is feasible for elderly patients with MIBC. The most common
toxicity is neutropenia, but no treatment-related mortality devel-
oped in our cohort. The conventional dose of gemcitabine com-
binedwith cisplatin or carboplatinwas well tolerated by the elderly
population. Patients and physicians should not be discouraged from
curative therapy. However, further investigations on chemotherapy
regimens and quality of life are needed.
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